Research progress on neoadjuvant immunotherapy for esophageal cancer
Yi Liang, Huang Hui, Yuan Zhiyong, Zhang Wencheng
Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China
Abstract：Neoadjuvant therapy, especially neoadjuvant chemoradiotherapy, has become the standard preoperative treatment for locally advanced resectable esophageal cancer, whereas the recurrence and distant metastasis rates after surgery remain high. In recent years, programmed cell death protein 1 (PD-1) / programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors have been widely adopted in immunotherapy for cancer. Whether PD-1/PD-L1 immune checkpoint inhibitors combined with neoadjuvant chemotherapy / neoadjuvant chemoradiotherapy could further improve clinical efficacy, increase the complete surgical resection rate and safety are current research hotspots. In this article, neoadjuvant immunotherapy combined with chemotherapy / radiochemotherapy for esophageal cancer was reviewed.
Yi Liang,Huang Hui,Yuan Zhiyong et al. Research progress on neoadjuvant immunotherapy for esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2023, 32(7): 638-643.
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249. DOI: 10.3322/caac.21660. [2] Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338. [3] 赫捷,李进,马军,等.中国临床肿瘤学会(CSCO)常见恶性肿瘤诊疗指南2021[M].北京:人民卫生出版社,2021:27-50. He J, Li J, Ma J, et al.Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Common Malignant Tumors 2021[M]. Beijing: People's Health Publishing House, 2021: 27-50. [4] Dhupar R, Van Der Kraak L, Pennathur A, et al. Targeting immune checkpoints in esophageal cancer: a high mutational load tumor[J]. Ann Thorac Surg, 2017,103(4):1340-1349. DOI: 10.1016/j.athoracsur.2016.12.011. [5] Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)[J]. Ann Surg Oncol, 2012,19(1):68-74. DOI: 10.1245/s10434-011-2049-9. [6] Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer[J]. J Clin Oncol, 2009,27(30):5062-5067. DOI: 10.1200/JCO.2009. 22.2083. [7] Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer[J]. J Clin Oncol, 2007,25(24):3719-3725. DOI: 10.1200/JCO.2006.10.4760. [8] Shapiro J, van Lanschot J, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015,16(9):1090-1098. DOI: 10.1016/S1470-2045(15)00040-6. [9] Yang H, Liu H, Chen YP, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018,36(27):2796-2803. DOI: 10.1200/JCO.2018.79.1483. [10] 冉刚, 周丽珍, 周超, 等. 局部中晚期食管癌术前新辅助放化疗联合食管癌根治术的临床研究[J].中华放射肿瘤学杂志,2017,26(8):874-879. DOI: 10.3760/cma.j.issn.1004-4221.2017.08.006. Ran G, Zhou LZ, Zhou C, et al. Clinical effect of preoperative neoadjuvant chemoradiotherapy plus esophagectomy in treatment of locally advanced esophageal cancer[J].Chin J Radiat Oncol,2017,26(8):874-879. DOI: 10.3760/cma.j.issn.1004-4221.2017.08.006. [11] Wang H, Tang H, Fang Y, et al. Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized clinical trial[J]. JAMA Surg, 2021,156(5):444-451. DOI: 10.1001/jamasurg.2021.0133. [12] Reynolds JV, Preston SR, O'Neill B, et al. Neo-AEGIS (neoadjuvant trial in adenocarcinoma of the esophagus and esophago-gastric junction international study): preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452)[J].J Clin Oncol,2021,39(15_suppl):4004. DOI: 10.1200/JCO.2021.39.15_suppl. 4004. [13] Kato K, Ito Y, Daiko H, et al.A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study[J]. J Clin Oncol,2022,40(4_suppl):238. DOI: 10.1200/JCO.2022.40.4_suppl.238. [14] Sun HB, Xing WQ, Liu XB, et al.Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)[J]. BMC Cancer, 2020,20(1):303. DOI: 10.1186/s12885-020-06824-2. [15] Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, et al. Paradigms on immunotherapy combinations with chemotherapy[J]. Cancer Discov, 2021,11(6):1353-1367. DOI: 10.1158/2159-8290.CD-20-1312. [16] Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors[J]. Nat Rev Clin Oncol, 2020,17(12):725-741. DOI: 10.1038/s41571-020-0413-z. [17] Liu J, Yang Y, Liu ZC, et al.Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma[J]. J Immunother Cancer, 2022,10(3):e004291. DOI: 10.1136/jitc-2021-004291. [18] Li JP, Liu J, Li ZY, et al.Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, open-label, single-arm, phase 2 study[J]. J Clin Oncol, 2021, 39(15_suppl):4028. DOI: 10.1200/JCO.2021.39.15_suppl.4028. [19] Wang Z.Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): a single-arm, open-label, phase Ib study[J]. J Clin Oncol, 2021, 39(15_suppl):4047. DOI: 10.1200/JCO.2021.39.15_suppl.4047. [20] Ma JQ, Zhang JF, Yang YN, et al.65P camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): a phase II, single-arm, exploratory research[J].Annals of Oncology,2021,32(Suppl 7):S1400. DOI:10.1016/j.annonc.2021.10.083. [21] Yang P, Zhou X, Yang XF, et al.Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study[J]. World J Surg Oncol, 2021,19(1):333. DOI: 10.1186/s12957-021-02446-5. [22] Yang WX, Xing XB, Yeung SJ, et al.Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma[J]. J Immunother Cancer, 2022,10(1):e003497.DOI: 10.1136/jitc-2021-003497. [23] Zhang ZY, Hong ZN, Xie SH, et al.Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)[J]. Ann Transl Med, 2021,9(21):1623. DOI: 10.21037/atm-21-5381. [24] Gu Y, Chen X, Wang D, et al. 175P a study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin,S-1 for resectable esophageal squamous cell carcinoma (ESCC)[J]. Annals of Oncology, 2020, 31(Suppl 6): S1307-S1308. DOI:10.1016/j.annonc. 2020.10.196. [25] Duan HT, Wang TH, Luo ZL, et al.A multicenter single-arm trial of sintilimab in combination with chemotherapy for neoadjuvant treatment of resectable esophageal cancer (SIN-ICE study)[J]. Ann Transl Med, 2021,9(22):1700. DOI: 10.21037/atm-21-6102. [26] Lv H, Tian Y, Huang C, et al.110P neoadjuvant PD-1 blockade combined with chemotherapy for patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC): a real world data analysis[J]. Annals of Oncology, 2021, 32(Suppl 7): S1423. DOI:10.1016/j.annonc.2021.10.128. [27] Shang X, Zhang C, Zhao G, et al. LBA3 safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (keystone-001): interim analysis of a prospective, single-arm, single-center, phase II trial[J]. Annals of Oncology, 2021, 32(Suppl 7):S1428-S1429. DOI:10.1016/j.annonc.2021.10.218. [28] Huang BJ, Shi HY, Gong XH, et al.Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma[J]. J Gastrointest Oncol, 2021,12(5):2013-2021. DOI: 10.21037/jgo-21-610. [29] Yan XL, Zhao JB, Lei J, et al.144P tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer (TD-NICE): a single arm, phase II study[J]. Annals of Oncology, 2021, 32: S1442. DOI:10.1016/j.annonc.2021.10.163. [30] Xing WQ, Zhao LD, Zheng Y, et al.The sequence of chemotherapy and toripalimab might influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell cancer-a phase II study[J]. Front Immunol, 2021,12:772450. DOI: 10.3389/fimmu.2021.772450. [31] Zheng Y, Liu XB, Sun HB, et al.A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909)[J]. Ann Transl Med, 2021,9(1):73. DOI: 10.21037/atm-20-5404. [32] Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature, 2015,520(7547):373-377. DOI: 10.1038/nature14292. [33] Hong MH, Kim HR, Park SY, et al.A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC)[J].J Clin Oncol,2019,37(15_suppl):4027. DOI: 10.1200/JCO.2019.37.15_suppl.4027. [34] Li CQ, Zhao SG, Zheng YY, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)[J]. Eur J Cancer, 2021,144:232-241. DOI: 10.1016/j.ejca.2020. 11.039. [35] Zheng YY, Li CQ, Yu BT, et al. Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: trial design[J]. JTCVS Open, 2022,9:293-299. DOI: 10.1016/j.xjon.2021.11.003. [36] Uboha NV, Maloney JD, McCarthy D, et al. Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer[J].J Clin Oncol,2019,37(15_suppl):4041. DOI: 10.1200/JCO.2019. 37.15_suppl.4041. [37] Kelly RJ, Zaidi AH, Canzoniero JV, et al. Multicenter phase II study of neoadjuvant nivolumab or nivolumab plus relatlimab (anti-LAG3 antibody) plus chemoradiotherapy in stage II/III esophageal/gastroesophageal junction (E/GEJ) carcinoma[J].J Clin Oncol,2022,40(4_suppl):321-321. DOI: 10.1200/JCO.2022.40.4_suppl.321. [38] van den Ende T, de Clercq NC, van Berge Henegouwen MI, et al. A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: the PERFECT trial[J]. J Clin Oncol,2019,37(15_suppl):4045. DOI: 10.1200/JCO.2019.37.15_suppl.4045. [39] van den Ende T, de Clercq NC, van Berge Henegouwen MI, et al. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT)[J]. Clin Cancer Res, 2021,27(12):3351-3359. DOI: 10.1158/1078-0432.CCR-20-4443. [40] Shah MA, Almhanna K, Iqbal S, et al.Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC)[J].J Clin Oncol, 2021,39(15_suppl):4005. DOI: 10.1200/JCO.2021.39.15_suppl.4005. [41] Yang Y, Tan LJ, Hu J, et al. Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China[J]. Dis Esophagus, 2022,35(11) :doac031. DOI: 10.1093/dote/doac031. [42] Zang YS, Dai C, Xu XM, et al. Comprehensive analysis of potential immunotherapy genomic biomarkers in1000 Chinese patients with cancer[J]. Cancer Med, 2019,8(10):4699-4708. DOI: 10.1002/cam4.2381. [43] Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy[J]. Science, 2018,362(6411): eaar3593. DOI: 10.1126/science.aar3593. [44] Liu J, Zhang JT, Qiao G, et al.190P transcriptomic molecular subtypes of esophageal squamous cell carcinoma predicted the prognosis and efficacy of neo-adjuvant immunotherapy[J]. Annals of Oncology, 2021, 32(Suppl 7): S1464. DOI:10.1016/j.annonc.2021.10.210.
2023, Vol. 32 
